Skip to main content
logo
Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.89
-7.21 (-10.29%)
Feb 25, 2026, 4:00 PM EST - Market closed

Cytokinetics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
88.0418.477.537.5970.43
Other Revenue
---87-
Revenue
88.0418.477.5394.5970.43
Revenue Growth (YoY)
376.56%145.34%-92.04%34.30%26.15%
Cost of Revenue
416.03339.41330.12240.81159.94
Gross Profit
-327.99-320.93-322.59-146.23-89.51
Selling, General & Admin
284.27215.31173.61177.9896.8
Operating Expenses
284.27215.31173.61177.9896.8
Operating Income
-612.26-536.25-496.21-324.2-186.31
Interest Expense
-103.87-86.51-57.67-51.16-29.33
Interest & Investment Income
48.4251.5327.6311.340.33
Other Non Operating Income (Expenses)
4-18.3---
EBT Excluding Unusual Items
-663.71-589.53-526.24-364.02-215.31
Other Unusual Items
-121.25---24.94-
Pretax Income
-784.96-589.53-526.24-388.96-215.31
Net Income
-784.96-589.53-526.24-388.96-215.31
Net Income to Common
-784.96-589.53-526.24-388.96-215.31
Shares Outstanding (Basic)
120112979077
Shares Outstanding (Diluted)
120112979077
Shares Change (YoY)
7.26%16.01%7.46%16.83%19.16%
EPS (Basic)
-6.54-5.26-5.45-4.33-2.80
EPS (Diluted)
-6.54-5.26-5.45-4.33-2.80
Free Cash Flow
--399.8-415.75-310.85-191.39
Free Cash Flow Per Share
--3.57-4.31-3.46-2.49
Gross Margin
----154.59%-127.09%
Operating Margin
-695.44%-2902.72%-6589.71%-342.75%-264.54%
Profit Margin
-891.60%-3191.11%-6988.63%-411.21%-305.72%
Free Cash Flow Margin
--2164.10%-5521.23%-328.64%-271.76%
EBITDA
-602.57-526.72-484.31-318.39-184.04
EBITDA Margin
-----261.31%
D&A For EBITDA
9.699.5311.895.812.28
EBIT
-612.26-536.25-496.21-324.2-186.31
EBIT Margin
-----264.54%
Revenue as Reported
88.0418.477.5394.5970.43
Updated Feb 24, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q